Clinical Trial

TACE Plus Atezolizumab/Bevacizumab and I-125 Seeds Brachytherapy for HCC With Branch PVTT

Recruiting
View on ClinicalTrials.gov →
Summary
The present study aimed to assess the effectiveness of the combination treatment of Atezolizumab/Bevacizumab, transcatheter arterial chemoembolization (TACE) and I-125 Seeds Brachytherapy (TACE-AB-I) in patients with advanced hepatocellular carcinoma (HCC) and portal vein tumor thrombosis (PVTT). The investigators confirmed that the combination therapy yielded better survival data than the combined administration of Atezolizumab/Bevacizumab and TACE (TACE-AB) in patients with advanced HCC and Type I/II PVTT (Based on Cheng's PVTT classification).
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-08-08; most recent amendment 2025-02-07.
Status change: Not Yet Recruiting → Recruiting 2025-02-07
Trial Details
NCT Number NCT05984511
Lead Sponsor Third Affiliated Hospital, Sun Yat-Sen University
Collaborators: Sun Yat-Sen University Cancer Center, Fifth Affiliated Hospital, Sun Yat-Sen University, Second Affiliated Hospital of Guangzhou Medical University, Maoming People's Hospital, Shandong Province Third hospital
Conditions Hepatocellular Carcinoma, Hepatic Portal Vein Tumor Invasion, Tumor Thrombus
Enrollment 234 participants
Start Date 2023-08-30
Primary Completion 2028-08-01 (estimated)
Study Completion 2029-08-01 (estimated)
Updated on ClinicalTrials.gov 2025-02-11